Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on April 26, 2022, to report its first quarter 2022 financial results. The report itself is brief, primarily referencing an attached press release (Exhibit 99.1) which contains the detailed financial information. Investors should refer to the press release for specifics on revenue, earnings, and any forward-looking guidance provided by the company for the period ending March 31, 2022. The filing indicates that the information furnished is not considered 'filed' under the Securities Exchange Act, meaning it's not subject to the same liabilities as formally filed registration statements, but it is still crucial for understanding the company's recent performance.
Key Highlights
- 1Edwards Lifesciences filed an 8-K on April 26, 2022, to announce its Q1 2022 financial results.
- 2The press release detailing the Q1 2022 financial results is furnished as Exhibit 99.1 and incorporated by reference.
- 3Investors should consult Exhibit 99.1 for specific financial performance data for the first quarter of 2022.
- 4The filing occurred on April 25, 2022, with the event date of the results also noted as April 25, 2022, implying the press release was issued concurrently or immediately after market close.
- 5The information is furnished, not filed, under Item 2.02 of Form 8-K, a common practice for earnings releases.